Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 05, 2022

BUY
$13.15 - $20.45 $106,501 - $165,624
8,099 Added 30.78%
34,409 $641,000
Q1 2022

May 06, 2022

BUY
$14.54 - $21.5 $382,547 - $565,665
26,310 New
26,310 $475,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.